Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly and Company (NYSE:LLY), a leading global pharmaceutical firm, finds itself at a pivotal juncture as it navigates a ...

Blockbuster weight loss medications from Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) lead Evaluate Pharma’s list of best-selling drugs projected for 2025 after the incretins pushed Bristol Myers ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

US-based pharmaceutical giant Eli Lilly is focusing on weight loss medications like Mounjaro (tirzepatide), which has proven ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Investing.com -- Eli Lilly and Company (NYSE:LLY) has projected its full-year global revenue for 2024 to reach around $45 billion, marking a 32% increase from the prior year. The company also ...

NEW YORK, Jan. 9, 2025 /PRNewswire/ -- Thrive Global announced today it is working with Eli Lilly and Company to embed behavior change tools and resources onto LillyDirect and into traditional ...

Guggenheim lowered the firm’s price target on Eli Lilly (LLY) to $973 from $995 and keeps a Buy rating on the shares. The firm is updating its ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and Eli Lilly’s competition with Novo Nordisk continues. ‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and strategic market expansion, a report showed on Tuesday. The drug will ...